Background/Aims: Transcriptional repression of tumor suppressor genes is determined by the quantity of promoter hypermethylation. We analyzed the methylation quantity of CDKN2B in pediatric myelodysplastic syndromes (MDS). Methods: Quantitative measurement of CDKN2B methylation was performed in 25 pediatric MDS patients and 12 controls using pyrosequencing, and the result was compared with those from 74 adult MDS cases and 31 adult controls. The association between CDKN2B methylation quantity and factors related to prognosis including bone marrow blast percentage and karyotype was analyzed. Results: Pediatric MDS patients showed a higher methylation level (MtL) of CDKN2B than pediatric controls (2.94 vs. 1.62; p = 0.031) but a lower level than adult MDS patients (8.76; p < 0.001). MtL was higher in pediatric MDS cases with >5% blasts than in pediatric controls (3.78 vs. 1.62; p = 0.052). Pediatric MDS cases with abnormal karyotype showed a higher MtL than pediatric controls (5.95 vs. 1.62; p = 0.045). Conclusions: We confirmed that methylation of CDKN2B is associated with the pathogenesis and prognosis in pediatric MDS. The difference in MtLs between pediatric and adult MDS might be related to the physiological hypermethylation of tumor suppressor genes in aging.

Keywords:
CDKN2B, Methylation, Myelodysplasia, Pyrosequencing
1.
Vidal DO, Paixão VA, Brait M, Souto EX, Caballero OL, Lopes LF, Vettore AL: Aberrant methylation in pediatric myelodysplastic syndrome. Leuk Res 2007;31:175-181.
2.
Rodrigues EF, Santos-Rebouças CB, Gonçalves Pimentel MM, Mencalha AL, Dobbin J, Da Costa ES, Fernandez Cde S, Bouzas LF, Abdelhay E, De Souza Fernandez T: Epigenetic alterations of p15 (INK4B) and p16 (INK4A) genes in pediatric primary myelodysplastic syndrome. Leuk Lymphoma 2010;51:1887-1894.
3.
Hasle H, Niemeyer CM, Chessells JM, Baumann I, Bennett JM, Kerndrup G, Head DR: A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases. Leukemia 2003;17:277-282.
4.
Niemeyer CM, Kratz CP, Hasle H: Pediatric myelodysplastic syndromes. Curr Treat Options Oncol 2005;6:209-214.
5.
Hasegawa D, Manabe A, Kubota T, Kawasaki H, Hirose I, Ohtsuka Y, Tsuruta T, Ebihara Y, Goto Y, Zhao XY, Sakashita K, Koike K, Isomura M, Kojima S, Hoshika A, Tsuji K, Nakahata T: Methylation status of the p15 and p16 genes in paediatric myelodysplastic syndrome and juvenile myelomonocytic leukaemia. Br J Haematol 2005;128:805-812.
6.
Mandel K, Dror Y, Poon A, Freedman MH: A practical, comprehensive classification for pediatric myelodysplastic syndromes: the CCC system. J Pediatr Hematol Oncol 2002;24:596-605.
7.
Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW: WHO Classification of Tumours of Hematopoietic and Lymphoid Tissues, ed 4. Lion, IARC press, 2008.
8.
Wong IH, Ng MH, Huang DP, Lee JC: Aberrant p15 promoter methylation in adult and childhood acute leukemias of nearly all morphologic subtypes: potential prognostic implications. Blood 2000;95:1942-1949.
9.
Kim M, Oh B, Kim SY, Park HK, Hwang SM, Kim TY, She CJ, Yang I, Yoon SS, Yoon JH, Lee DS: p15INK4b methylation correlates with thrombocytopenia, blast percentage, and survival in myelodysplastic syndromes in a dose dependent manner: quantitation using pyrosequencing study. Leuk Res 2010;34:718-722.
10.
Wong IH: Methylation profiling of human cancers in blood: molecular monitoring and prognostication (review). Int J Oncol 2001;19:1319-1324.
11.
Uchida T, Kinoshita T, Nagai H, Nakahara Y, Saito H, Hotta T, Murate T: Hypermethylation of the p15INK4b gene in myelodysplastic syndromes. Blood 1997;90:1403-1409.
12.
Quesnel B, Guillerm G, Vereecque R, Wattel E, Preudhomme C, Bauters F, Vanrumbeke M, Fenaux P: Methylation of the p15 (INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression. Blood 1998;91:2985-2990.
13.
Tien HF, Tang JH, Tsay W, Liu MC, Lee FY, Wang CH, Chen YC, Shen MC: Methylation of the p15 (INK4B) gene in myelodysplastic syndrome: it can be detected early at diagnosis or during disease progression and is highly associated with leukaemic transformation. Br J Haematol 2001;112:148-154.
14.
Hsieh CL: Dependence of transcriptional repression on CpG methylation density. Mol Cell Biol 1994;14:5487-5494.
15.
Herman JG, Graff JR, Myöhänen S, Nelkin BD, Baylin SB: Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996;93:9821-9826.
16.
Hasle H: Myelodysplastic and myeloproliferative disorders in children. Curr Opin Pediatr 2007;19:1-8.
17.
Jones PA, Gonzalgo ML: Altered DNA methylation and genome instability: a new pathway to cancer? Proc Natl Acad Sci USA 1997;94:2103-2105.
18.
Lengauer C, Kinzler KW, Vogelstein B: DNA methylation and genetic instability in colorectal cancer cells. Proc Natl Acad Sci USA 1997;94:2545-2550.
19.
Habano W, Sugai T, Jiao YF, Nakamura S: Novel approach for detecting global epigenetic alterations associated with tumor cell aneuploidy. Int J Cancer 2007;121:1487-1493.
20.
Boks MP, Derks EM, Weisenberger DJ, Strengman E, Janson E, Sommer IE, Kahn RS, Ophoff RA: The relationship of DNA methylation with age, gender and genotype in twins and healthy controls. PLoS One 2009;4:e6767.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.